Peripheral T-cell Lymphoma in Children and Adolescents

Mahmoud, Rabah Al; Weitzman, Sheila; Schechter, Tal; Ngan, Bo; Abdelhaleem, Mohammed; Alexander, Sarah

doi:10.1097/mph.0b013e3182707592

Cited by 26 publications

(29 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recent reviews on PTCL in pediatric and adolescent patients show that survival rates still are poor compared to other NHL sub-entities of this age group and that treatment results vary between PTCL subgroups [1][2][3][9][10][11].…”

Section: Introductionmentioning

confidence: 98%

Non-anaplastic peripheral T cell lymphoma in children and adolescents—an international review of 143 cases

et al. 2016

View full text Add to dashboard Cite

Peripheral T cell lymphomas (PTCL) are rare in children and adolescents, and data about outcome and treatment results are scarce. The present study is a joint, international, retrospective analysis of 143 reported cases of non-anaplastic PTCL in patients <19 years of age, with a focus on treatment and outcome features. One hundred forty-three patients, between 0.3 and 18.7 years old, diagnosed between 2000 and 2015 were included in the study. PTCL not otherwise specified was the largest subgroup, followed by extranodal NK/T cell lymphoma, hepatosplenic T cell lymphoma (HS TCL), and subcutaneous panniculitis-like T cell lymphoma (SP TCL). Probability of overall survival (pOS) at 5 years for the whole group was 0.56 ± 0.05, and probability of event-free survival was (pEFS) 0.45 ± 0.05. Patients with SP TCL had a good outcome with 5-year pOS of 0.78 ± 0.1 while patients with HS TCL were reported with 5-year pOS of only 0.13 ± 0.12. Twenty-five percent of the patients were reported to have a pre-existing condition, and this group had a dismal outcome with 5-year pOS of 0.29 ± 0.09. The distribution of non-anaplastic PTCL subtypes in pediatric and adolescent patients differs from what is reported in adult patients. Overall outcome depends on the subtype with some doing better than others. Pre-existing conditions are frequent and associated with poor outcomes. There is a clear need for subtype-based treatment recommendations for children and adolescents with PTCL.

show abstract

Section: Introductionmentioning

confidence: 98%

Non-anaplastic peripheral T cell lymphoma in children and adolescents—an international review of 143 cases

et al. 2016

View full text Add to dashboard Cite

show abstract

“…In Western countries, PTCL accounts for 15–20% of aggressive lymphomas and 5–10% of all NHL [18]. PTCL remains extremely difficult to treat; most PTCL subtypes become refractory to chemotherapy regimens and relapse [19]. Among the various entities of PTCL, ATLL harbors the worst prognosis, with a 5-year overall survival (OS) and failure-free survival (FFS) of 14% and 12%, respectively [18].…”

Section: Introductionmentioning

confidence: 99%

Fully Human Antagonistic Antibodies against CCR4 Potently Inhibit Cell Signaling and Chemotaxis

Hagemann¹,

Gunnarsson²,

Geraudie³

et al. 2014

PLoS ONE

View full text Add to dashboard Cite

BackgroundCC chemokine receptor 4 (CCR4) represents a potentially important target for cancer immunotherapy due to its expression on tumor infiltrating immune cells including regulatory T cells (Tregs) and on tumor cells in several cancer types and its role in metastasis.MethodologyUsing phage display, human antibody library, affinity maturation and a cell-based antibody selection strategy, the antibody variants against human CCR4 were generated. These antibodies effectively competed with ligand binding, were able to block ligand-induced signaling and cell migration, and demonstrated efficient killing of CCR4-positive tumor cells via ADCC and phagocytosis. In a mouse model of human T-cell lymphoma, significant survival benefit was demonstrated for animals treated with the newly selected anti-CCR4 antibodies.SignificanceFor the first time, successful generation of anti- G-protein coupled chemokine receptor (GPCR) antibodies using human non-immune library and phage display on GPCR-expressing cells was demonstrated. The generated anti-CCR4 antibodies possess a dual mode of action (inhibition of ligand-induced signaling and antibody-directed tumor cell killing). The data demonstrate that the anti-tumor activity in vivo is mediated, at least in part, through Fc-receptor dependent effector mechanisms, such as ADCC and phagocytosis. Anti-CC chemokine receptor 4 antibodies inhibiting receptor signaling have potential as immunomodulatory antibodies for cancer.

show abstract

“…Patients often exhibit generalized lymphadenopathy and B symptoms occur about half the time but do not correlate with stage. As with ALCL, patients with stage I or II disease have a better outcome than patients with higher stage disease but the outcome is significantly inferior to that of children with ALCL 61,62 .…”

Section: Peripheral T-cell Lymphomamentioning

confidence: 96%

NK/T-cell lymphomas in children

Lai

Dunleavy

2013

Best Practice & Research Clinical Haematology

View full text Add to dashboard Cite

In children, T and NK-cell lymphomas are uncommon in Western Countries. While there has been significant experience treating T-cell lymphoblastic lymphoma (T-LBL) and anaplastic large cell lymphoma (ALCL), other subtypes are very rarely encountered and there are no standard approaches to their management. There are many challenges in defining optimal therapy for many of these diseases but recent progress in elucidating their biology has led to new molecular insights and identified interesting targets for novel drug discovery. In this review, we discuss these disorders in children, how they are approached therapeutically and what lies on the horizon with respect to novel treatment approaches.

show abstract

Peripheral T-cell Lymphoma in Children and Adolescents

Abstract: Children with PTCL have an unfavorable outcome. A standard approach to management of pediatric PTCL needs to be established to improve outcome. Because of the rarity of this condition, this will require collaborative studies.

Cited by 26 publications

References 38 publications

Non-anaplastic peripheral T cell lymphoma in children and adolescents—an international review of 143 cases

Non-anaplastic peripheral T cell lymphoma in children and adolescents—an international review of 143 cases

Fully Human Antagonistic Antibodies against CCR4 Potently Inhibit Cell Signaling and Chemotaxis

NK/T-cell lymphomas in children

Contact Info

Product

Resources

About